The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors
Open accessAbstract
Between December 1996 and September 1998, 13 patients with advanced recurrent malignant brain tumors (9 with glioblastoma multiforme, 1 with gliosarcoma, and 3 with anaplastic astrocytoma) were treated with a single intratumoral injection of 2 x 10(9), 2 x 10(10), 2 x 10(11), or 2 x 10(12) vector particles (VP) of a replication-defective adenoviral vector bearing the herpes simplex virus thymidine kinase gene driven by the Rous sarcoma virus promoter (Adv.RSVtk), followed by ganciclovir (GCV) treatment. The VP to infectious unit ratio was 20:1. Our primary objective was to determine the safety of this treatment. Injection of Adv.RSVtk in doses <==2 x 10(11) VP, followed by GCV, was safely tolerated. Patients treated with the highest dose, 2 x 10(12) VP, exhibited central nervous system toxicity with confusion, hyponatremia, and seizures. One patient is living and stable 29.2 months after treatment. Two patients survived >25 months before succumbing to tumor progression. Ten patients died within 10 months of treatment, 9 from tumor progression and 1 with sepsis and endocarditis. Neuropathologic examination of postmortem tissue demonstrated cavitation at the injection site, intratumoral foci of coagulative necrosis, and variable infiltration of the residual tumor with macrophages and lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manipulation of Adenovirus Vectors
Graham, F. L., & Prevec, L. (2003) · Gene Transfer and Expression Protocols · doi:10.1385/0-89603-178-0:109 · Cited by 752
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., & Woo, S. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3054 · Cited by 478
Self-citationMorral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12816 · Cited by 409
Survival and Functional Status after Resection of Recurrent Glioblastoma Multiforme
Barker, F. G., Chang, S. M., Gutin, P. H., Malec, M. K., McDermott, M. W., Prados, M. D., & Wilson, C. B. (1998) · Neurosurgery · doi:10.1097/00006123-199804000-00013 · Cited by 330
Dewey, R. A., Morrissey, G., Cowsill, C. M., Stone, D., Bolognani, F., Dodd, N. J. F., Southgate, T. D., Klatzmann, D., Lassmann, H., Castro, M. G., et al. (1999) · Nature Medicine · doi:10.1038/15207 · Cited by 311
Klatzmann, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.-L., Philippon, J., & Glioblastoma, S. G. O. G. T. F. (1998) · Human Gene Therapy · doi:10.1089/10430349850019436 · Cited by 269
Aa, E., Saavedra, A., Zhang, H., Kucharczuk, J. C., Dc, S., Fishman, G. I., Km, A., Kaiser, L. R., & Albelda, S. (1996) · PubMed · Cited by 259
Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A. G., & Barbier, N. (1999) · Human Gene Therapy · doi:10.1089/10430349950016979 · Cited by 247
Shrieve, D. C., Alexander, E., Black, P. M., Wen, P. Y., Fine, H. A., Kooy, H. M., & Loeffler, J. S. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.90.1.0072 · Cited by 224
Cited by
Prospects for cationic polymers in gene and oligonucleotide therapy against cancer
Merdan, T., Kopec̆ek, J., & Kissel, T. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00046-7 · Cited by 785
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Immonen, A., Vapalahti, M., Tyynelä, K., Hurskainen, H., Sandmair, A., Vanninen, R., Langford, G., Murray, N., & Ylä-Herttuala, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.002 · Cited by 390
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Metadata
- Authors
- Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S.-H., Woo, S. L. C., & Grossman, R. G.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2000-02
- Volume
- 1
- Issue
- 2
- Pages
- 195-203
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2102236923
- Cited by
- 262
- References
- 29
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors. https://app.cochat.ai/papers/10.1006/mthe.2000.0030
- The paper
- Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S.-H., Woo, S. L. C., & Grossman, R. G. (2000). Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors. Molecular Therapy. https://doi.org/10.1006/mthe.2000.0030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.